Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human breast carcinoma tissue labelling BIRC6 with ab19609 at 1/5000 (0.2µg/ml). Detection: DAB.
Western blot - BIRC6 antibody (ab19609)
All lanes : Anti-BIRC6 antibody (ab19609) at 1/10000 dilution
Lane 1 : HeLa whole cell lysate at 20 µg Lane 2 : HeLa whole cell lysate at 50 µg Lane 3 : HeLa S100 extract at 20 µg Lane 4 : HeLa S100 extract at 50 µg
Predicted band size : 528 kDa
Detection of Human BIRC6 by western blot. Lane 1: 20 µg of HeLa whole cell lysate. Lane 2: 50 µg of HeLa whole cell lysate. Lane 3: 20 µg of HeLa S100 extract. Lane 4: 50 µg of HeLa S100 extract.
Affinity purified anti-BIRC antibody (ab19609) was used at a 1/10,000 dilution.
Immunoprecipitation - BIRC6 antibody (ab19609)
Detection of human BIRC6 by Immunoprecipitation. Affinity purified ab19609 used at 2mcg/mg lysate (whole cell lysate (10mg) from HeLa cells. The immunoprecipitate was resolved by SDS-PAGE and stained with Coomassie Blue. The band that is BIRC6 was confirmed by mass spectrometry.
ICC/IF image of ab19609 stained HeLa cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab19609, 5µg/ml) overnight at +4°C. The secondary antibody (green) was ab96899, DyLight® 488 goat anti-rabbit IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
References for Anti-BIRC6 antibody (ab19609)
This product has been referenced in:
Wilding C et al. ?-Synuclein antibodies have neuroprotective potential on neuroretinal cells via proteins of the mitochondrial apoptosis pathway. PLoS One9:e90737 (2014).
Read more (PubMed: 24595072) »
Lamers F et al. Identification of BIRC6 as a novel intervention target for neuroblastoma therapy. BMC Cancer12:285 (2012).
Read more (PubMed: 22788920) »